{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:12:44Z","timestamp":1791054764763,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T00:00:00Z","timestamp":1316131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T00:00:00Z","timestamp":1316131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/leu.2011.248","type":"journal-article","created":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T14:30:54Z","timestamp":1316183454000},"page":"795-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Involvement of the Syk\u2013mTOR pathway in follicular lymphoma cell invasion and angiogenesis"],"prefix":"10.1038","volume":"26","author":[{"given":"S","family":"Fruchon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kheirallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Al Saati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Leseux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Fourni\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bezombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,16]]},"reference":[{"key":"BFleu2011248_CR1","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","volume":"108","author":"L Leseux","year":"2006","unstructured":"Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108: 4156\u20134162.","journal-title":"Blood"},{"key":"BFleu2011248_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2007-04-085092","volume":"111","author":"L Leseux","year":"2008","unstructured":"Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008; 111: 285\u2013291.","journal-title":"Blood"},{"key":"BFleu2011248_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.yexcr.2010.09.011","volume":"317","author":"S Tauzin","year":"2011","unstructured":"Tauzin S, Ding H, Burdevet D, Borisch B, Hoessli DC . Membrane-associated signaling in human B-lymphoma lines. Exp Cell Res 2011; 317: 151\u2013162.","journal-title":"Exp Cell Res"},{"key":"BFleu2011248_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.drudis.2010.05.001","volume":"15","author":"M Riccaboni","year":"2010","unstructured":"Riccaboni M, Bianchi I, Petrillo P . Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010; 15: 517\u2013530.","journal-title":"Drug Discov Today"},{"key":"BFleu2011248_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A Mocsai","year":"2010","unstructured":"Mocsai A, Ruland J, Tybulewicz VL . The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010; 10: 387\u2013402.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2011248_CR6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bbamcr.2009.03.004","volume":"1793","author":"RL Geahlen","year":"2009","unstructured":"Geahlen RL . Syk and pTyr\u2019d: signaling through the B cell antigen receptor. Biochim Biophys Acta 2009; 1793: 1115\u20131127.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2011248_CR7","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1182\/blood-2005-12-030387","volume":"108","author":"J Schymeinsky","year":"2006","unstructured":"Schymeinsky J, Sindrilaru A, Frommhold D, Sperandio M, Gerstl R, Then C et al. The Vav binding site of the non-receptor tyrosine kinase Syk at Tyr 348 is critical for beta2 integrin (CD11\/CD18)-mediated neutrophil migration. Blood 2006; 108: 3919\u20133927.","journal-title":"Blood"},{"key":"BFleu2011248_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/bbrc.2001.5355","volume":"286","author":"R Inatome","year":"2001","unstructured":"Inatome R, Yanagi S, Takano T, Yamamura H . A critical role for Syk in endothelial cell proliferation and migration. Biochem Biophys Res Commun 2001; 286: 195\u2013199.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu2011248_CR9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2010-07-295659","volume":"117","author":"G Pearce","year":"2011","unstructured":"Pearce G, Audzevich T, Jessberger R . SYK regulates B-cell migration by phosphorylation of the F-actin interacting protein SWAP-70. Blood 2011; 117: 1574\u20131584.","journal-title":"Blood"},{"key":"BFleu2011248_CR10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/35021086","volume":"406","author":"PJ Coopman","year":"2000","unstructured":"Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000; 406: 742\u2013747.","journal-title":"Nature"},{"key":"BFleu2011248_CR11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/j.0022-202X.2005.23685.x","volume":"124","author":"C Hoeller","year":"2005","unstructured":"Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R et al. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol 2005; 124: 1293\u20131299.","journal-title":"J Invest Dermatol"},{"key":"BFleu2011248_CR12","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3748\/wjg.v10.i12.1815","volume":"10","author":"S Wang","year":"2004","unstructured":"Wang S, Ding YB, Chen GY, Xia JG, Wu ZY . Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2004; 10: 1815\u20131818.","journal-title":"World J Gastroenterol"},{"key":"BFleu2011248_CR13","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1074\/jbc.M208905200","volume":"278","author":"GH Mahabeleshwar","year":"2003","unstructured":"Mahabeleshwar GH, Kundu GC . Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3\u2032-kinase activity in breast cancer cells. J Biol Chem 2003; 278: 6209\u20136221.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR14","doi-asserted-by":"publisher","first-page":"8806","DOI":"10.1074\/jbc.M507305200","volume":"281","author":"J Lu","year":"2006","unstructured":"Lu J, Lin WH, Chen SY, Longnecker R, Tsai SC, Chen CL et al. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 2006; 281: 8806\u20138814.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR15","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1158\/0008-5472.CAN-07-0331","volume":"67","author":"S Luangdilok","year":"2007","unstructured":"Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L et al. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007; 67: 7907\u20137916.","journal-title":"Cancer Res"},{"key":"BFleu2011248_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2010.01.011","volume":"32","author":"E Letellier","year":"2010","unstructured":"Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010; 32: 240\u2013252.","journal-title":"Immunity"},{"key":"BFleu2011248_CR17","doi-asserted-by":"publisher","first-page":"11322","DOI":"10.1074\/jbc.M512546200","volume":"281","author":"G Chakraborty","year":"2006","unstructured":"Chakraborty G, Rangaswami H, Jain S, Kundu GC . Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 2006; 281: 11322\u201311331.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","volume":"25","author":"EI Deryugina","year":"2006","unstructured":"Deryugina EI, Quigley JP . Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9\u201334.","journal-title":"Cancer Metastasis Rev"},{"key":"BFleu2011248_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/1568009053765799","volume":"5","author":"P Vihinen","year":"2005","unstructured":"Vihinen P, Ala-aho R, Kahari VM . Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5: 203\u2013220.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFleu2011248_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52\u201367.","journal-title":"Cell"},{"key":"BFleu2011248_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J . The biology of VEGF and its receptors. Nat Med 2003; 9: 669\u2013676.","journal-title":"Nat Med"},{"key":"BFleu2011248_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/annonc\/mdn666","volume":"20","author":"J Ruan","year":"2009","unstructured":"Ruan J, Hajjar K, Rafii S, Leonard JP . Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma. Ann Oncol 2009; 20: 413\u2013424.","journal-title":"Ann Oncol"},{"key":"BFleu2011248_CR23","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1182\/blood-2004-01-0226","volume":"104","author":"ES Wang","year":"2004","unstructured":"Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA . Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893\u20132902.","journal-title":"Blood"},{"key":"BFleu2011248_CR24","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0959-8049(03)00427-1","volume":"39","author":"L Manenti","year":"2003","unstructured":"Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003; 39: 1948\u20131956.","journal-title":"Eur J Cancer"},{"key":"BFleu2011248_CR25","first-page":"1411","volume":"2","author":"Y Ohta","year":"1996","unstructured":"Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996; 2: 1411\u20131416.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011248_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1368-5031.2004.0023.x","volume":"58","author":"B Hazar","year":"2004","unstructured":"Hazar B, Polat G, Seyrek E, Bagdatoglglu O, Kanik A, Tiftik N . Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Int J Clin Pract 2004; 58: 139\u2013143.","journal-title":"Int J Clin Pract"},{"key":"BFleu2011248_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3109\/10428190009113379","volume":"39","author":"AE Kossakowska","year":"2000","unstructured":"Kossakowska AE, Urbanski SJ, Janowska-Wieczorek A . Matrix metalloproteinases and their tissue inhibitors\u2014expression, role and regulation in human malignant non-Hodgkin\u2019s lymphomas. Leuk Lymphoma 2000; 39: 485\u2013493.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2011248_CR28","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","volume":"96","author":"P Salven","year":"2000","unstructured":"Salven P, Orpana A, Teerenhovi L, Joensuu H . Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712\u20133718.","journal-title":"Blood"},{"key":"BFleu2011248_CR29","doi-asserted-by":"publisher","first-page":"32662","DOI":"10.1074\/jbc.274.46.32662","volume":"274","author":"LO Beitz","year":"1999","unstructured":"Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM . SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem 1999; 274: 32662\u201332666.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR30","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1021\/jm800295d","volume":"51","author":"AJ Folkes","year":"2008","unstructured":"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522\u20135532.","journal-title":"J Med Chem"},{"key":"BFleu2011248_CR31","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1124\/dmd.110.032912","volume":"38","author":"L Salphati","year":"2010","unstructured":"Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010; 38: 1436\u20131442.","journal-title":"Drug Metab Dispos"},{"key":"BFleu2011248_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1600-0609.2008.01113.x","volume":"81","author":"H Pennanen","year":"2008","unstructured":"Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T . Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Eur J Haematol 2008; 81: 289\u2013297.","journal-title":"Eur J Haematol"},{"key":"BFleu2011248_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/10428190902889270","volume":"50","author":"HF Negaard","year":"2009","unstructured":"Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Ostenstad B et al. Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50: 998\u20131004.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2011248_CR34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.2353\/ajpath.2007.060901","volume":"170","author":"D Gratzinger","year":"2007","unstructured":"Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ, Hammer AS et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007; 170: 1362\u20131369.","journal-title":"Am J Pathol"},{"key":"BFleu2011248_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128\u2013135.","journal-title":"Nat Med"},{"key":"BFleu2011248_CR36","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1182\/blood-2008-05-158618","volume":"113","author":"RM Young","year":"2009","unstructured":"Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009; 113: 2508\u20132516.","journal-title":"Blood"},{"key":"BFleu2011248_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/jpet.106.109058","volume":"319","author":"S Braselmann","year":"2006","unstructured":"Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006; 319: 998\u20131008.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu2011248_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/cncr.11905","volume":"100","author":"K Sakata","year":"2004","unstructured":"Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 2004; 100: 356\u2013365.","journal-title":"Cancer"},{"key":"BFleu2011248_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","volume":"114","author":"MP Quiroga","year":"2009","unstructured":"Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029\u20131037.","journal-title":"Blood"},{"key":"BFleu2011248_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1872-034X.2008.00449.x","volume":"39","author":"JS Chen","year":"2009","unstructured":"Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ et al. Involvement of PI3K\/PTEN\/AKT\/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009; 39: 177\u2013186.","journal-title":"Hepatol Res"},{"key":"BFleu2011248_CR41","doi-asserted-by":"publisher","first-page":"29614","DOI":"10.1074\/jbc.M604013200","volume":"281","author":"S Han","year":"2006","unstructured":"Han S, Ritzenthaler JD, Sitaraman SV, Roman J . Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J Biol Chem 2006; 281: 29614\u201329624.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood-2002-04-1251","volume":"101","author":"K Jiang","year":"2003","unstructured":"Jiang K, Zhong B, Ritchey C, Gilvary DL, Hong-Geller E, Wei S et al. Regulation of Akt-dependent cell survival by Syk and Rac. Blood 2003; 101: 236\u2013244.","journal-title":"Blood"},{"key":"BFleu2011248_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10555-007-9077-8","volume":"26","author":"H Seeliger","year":"2007","unstructured":"Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ . Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007; 26: 611\u2013621.","journal-title":"Cancer Metastasis Rev"},{"key":"BFleu2011248_CR44","first-page":"489","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL . The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews 2002; 2: 489\u2013501.","journal-title":"Nature Reviews"},{"key":"BFleu2011248_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ . The TOR pathway: a target for cancer therapy. Nat Rev 2004; 4: 335\u2013348.","journal-title":"Nat Rev"},{"key":"BFleu2011248_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation-2010.1.265","volume":"2010","author":"TE Witzig","year":"2010","unstructured":"Witzig TE, Gupta M . Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010: 265\u2013270.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu2011248_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2010","unstructured":"Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2010; 25: 341\u2013347.","journal-title":"Leukemia"},{"key":"BFleu2011248_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev 2009; 9: 550\u2013562.","journal-title":"Nat Rev"},{"key":"BFleu2011248_CR49","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/leu.2010.154","volume":"24","author":"PM Bhende","year":"2010","unstructured":"Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B . The dual PI3K\/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010; 24: 1781\u20131784.","journal-title":"Leukemia"},{"key":"BFleu2011248_CR50","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","volume":"28","author":"SM Smith","year":"2010","unstructured":"Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740\u20134746.","journal-title":"J Clin Oncol"},{"key":"BFleu2011248_CR51","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/bjc.2011.83","volume":"104","author":"JM Garcia-Martinez","year":"2011","unstructured":"Garcia-Martinez JM, Wullschleger S, Preston G, Guichard S, Fleming S, Alessi DR et al. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN\/LKB1-deficient mice. Br J Cancer 2011; 104: 1116\u20131125.","journal-title":"Br J Cancer"},{"key":"BFleu2011248_CR52","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1242\/jcs.045112","volume":"123","author":"MD Schaller","year":"2010","unstructured":"Schaller MD . Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010; 123: 1007\u20131013.","journal-title":"J Cell Sci"},{"key":"BFleu2011248_CR53","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1242\/jcs.045658","volume":"122","author":"GP Coffey","year":"2009","unstructured":"Coffey GP, Rajapaksa R, Liu R, Sharpe O, Kuo CC, Krauss SW et al. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci 2009; 122: 3137\u20133144.","journal-title":"J Cell Sci"},{"key":"BFleu2011248_CR54","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1158\/0008-5472.CAN-07-6700","volume":"68","author":"M Iiizumi","year":"2008","unstructured":"Iiizumi M, Bandyopadhyay S, Pai SK, Watabe M, Hirota S, Hosobe S et al. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 2008; 68: 7613\u20137620.","journal-title":"Cancer Res"},{"key":"BFleu2011248_CR55","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1158\/0008-5472.CAN-04-3135","volume":"65","author":"X Wan","year":"2005","unstructured":"Wan X, Mendoza A, Khanna C, Helman LJ . Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406\u20132411.","journal-title":"Cancer Res"},{"key":"BFleu2011248_CR56","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1074\/jbc.M407805200","volume":"280","author":"KD Moon","year":"2005","unstructured":"Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML et al. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem 2005; 280: 1543\u20131551.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR57","doi-asserted-by":"publisher","first-page":"45643","DOI":"10.1074\/jbc.M404097200","volume":"279","author":"HD Skinner","year":"2004","unstructured":"Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH . Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase\/AKT signaling. J Biol Chem 2004; 279: 45643\u201345651.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR58","doi-asserted-by":"publisher","first-page":"29993","DOI":"10.1074\/jbc.M414530200","volume":"280","author":"D Bradbury","year":"2005","unstructured":"Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks J, Knox A . Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2\/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005; 280: 29993\u201330000.","journal-title":"J Biol Chem"},{"key":"BFleu2011248_CR59","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.1158\/0008-5472.CAN-05-2231","volume":"65","author":"L Wang","year":"2005","unstructured":"Wang L, Devarajan E, He J, Reddy SP, Dai JL . Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res 2005; 65: 10289\u201310297.","journal-title":"Cancer Res"},{"key":"BFleu2011248_CR60","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ijc.25134","volume":"127","author":"C Chetty","year":"2010","unstructured":"Chetty C, Lakka SS, Bhoopathi P, Rao JS . MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K\/AKT signaling in A549 lung cancer cells. Int J Cancer 2010; 127: 1081\u20131095.","journal-title":"Int J Cancer"},{"key":"BFleu2011248_CR61","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/1541-7786.MCR-07-0366","volume":"6","author":"D Belotti","year":"2008","unstructured":"Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008; 6: 525\u2013534.","journal-title":"Mol Cancer Res"},{"key":"BFleu2011248_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00277-009-0777-8","volume":"89","author":"SI Labidi","year":"2009","unstructured":"Labidi SI, Menetrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T et al. Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival. Ann Hematol 2009; 89: 25\u201333.","journal-title":"Ann Hematol"},{"key":"BFleu2011248_CR63","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","volume":"111","author":"L Chen","year":"2008","unstructured":"Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111: 2230\u20132237.","journal-title":"Blood"},{"key":"BFleu2011248_CR64","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","volume":"115","author":"M Buchner","year":"2010","unstructured":"Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497\u20134506.","journal-title":"Blood"},{"key":"BFleu2011248_CR65","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578\u20132585.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011248","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:39:39Z","timestamp":1648737579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,16]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["BFleu2011248"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.248","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,16]]},"assertion":[{"value":"7 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}